DNTH Quote, Financials, Valuation and Earnings

Halozyme Therapeutics, Inc. has a net margin of -9284.09% compared to Dianthus Therapeutics, Inc.'s net margin of 49.46%. Dianthus Therapeutics, Inc.'s return on equity of -33.81% beat Halozyme Therapeutics, Inc.'s return on equity of 139.43%.

Dianthus Therapeutics, Inc. has a consensus price target of $63.05, signalling upside risk potential of 42.45%. On the other hand Halozyme Therapeutics, Inc. has an analysts' consensus of $76.00 which suggests that it could grow by 20.01%. Given that Dianthus Therapeutics, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Dianthus Therapeutics, Inc. is more attractive than Halozyme Therapeutics, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.558, which suggesting that the stock is 55.828% more volatile than S&P 500. In comparison Halozyme Therapeutics, Inc. has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.224%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Halozyme Therapeutics, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $396K, which are smaller than Halozyme Therapeutics, Inc. quarterly revenues of $354.3M. Dianthus Therapeutics, Inc.'s net income of -$36.8M is lower than Halozyme Therapeutics, Inc.'s net income of $175.2M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Halozyme Therapeutics, Inc.'s PE ratio is 13.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 519.25x versus 6.40x for Halozyme Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics, Inc. has a net margin of -9284.09% compared to Dianthus Therapeutics, Inc.'s net margin of -135.28%. Dianthus Therapeutics, Inc.'s return on equity of -33.81% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

Dianthus Therapeutics, Inc. has a consensus price target of $63.05, signalling upside risk potential of 42.45%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 275%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Dianthus Therapeutics, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.558, which suggesting that the stock is 55.828% more volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $396K, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Dianthus Therapeutics, Inc.'s net income of -$36.8M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 519.25x versus 2.91x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexicon Pharmaceuticals, Inc. has a net margin of -9284.09% compared to Dianthus Therapeutics, Inc.'s net margin of -90.04%. Dianthus Therapeutics, Inc.'s return on equity of -33.81% beat Lexicon Pharmaceuticals, Inc.'s return on equity of -49.19%.

Dianthus Therapeutics, Inc. has a consensus price target of $63.05, signalling upside risk potential of 42.45%. On the other hand Lexicon Pharmaceuticals, Inc. has an analysts' consensus of $2.88 which suggests that it could grow by 105.71%. Given that Lexicon Pharmaceuticals, Inc. has higher upside potential than Dianthus Therapeutics, Inc., analysts believe Lexicon Pharmaceuticals, Inc. is more attractive than Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.558, which suggesting that the stock is 55.828% more volatile than S&P 500. In comparison Lexicon Pharmaceuticals, Inc. has a beta of 0.963, suggesting its less volatile than the S&P 500 by 3.666%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Lexicon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $396K, which are smaller than Lexicon Pharmaceuticals, Inc. quarterly revenues of $14.2M. Dianthus Therapeutics, Inc.'s net income of -$36.8M is lower than Lexicon Pharmaceuticals, Inc.'s net income of -$12.8M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Lexicon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 519.25x versus 7.16x for Lexicon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of -9284.09% compared to Dianthus Therapeutics, Inc.'s net margin of 40.17%. Dianthus Therapeutics, Inc.'s return on equity of -33.81% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

Dianthus Therapeutics, Inc. has a consensus price target of $63.05, signalling upside risk potential of 42.45%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $49.60 which suggests that it could grow by 1.39%. Given that Dianthus Therapeutics, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Dianthus Therapeutics, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Dianthus Therapeutics, Inc. has a beta of 1.558, which suggesting that the stock is 55.828% more volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 11.026%.

Dianthus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dianthus Therapeutics, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Dianthus Therapeutics, Inc. quarterly revenues are $396K, which are smaller than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Dianthus Therapeutics, Inc.'s net income of -$36.8M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Dianthus Therapeutics, Inc.'s price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 7.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dianthus Therapeutics, Inc. is 519.25x versus 3.19x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.